Latest Zyomyx Inc. Stories
HAYWARD, Calif., Nov. 17 /PRNewswire/ -- Zyomyx, Inc., a leader in chip-based bioanalysis technologies, today announced that its readerless CD4 point-of-care (POC) technology was selected by Imperial College London's CD4 Initiative as the best-performing POC test method for measuring CD4 T-cell count in HIV/AIDS patients. Zyomyx's CD4 assay is now the only remaining POC product being supported by the CD4 Initiative. With this announcement, Zyomyx is currently entering the commercial...
- A stinking tobacco.
- Offal; waste animal product; organic matter unfit for consumption.